Medical Co. Ready for a Transformative F2025
Research Report
Revolutionary AI Tools Take Center Stage in Medical Education Symposium
Pharma Stock Has Significant Upside Potential, Analyst Says
Research Report
AI Healthcare Co. With 'Bright' Outlook Closes Placement
Biotech Shares Positive Phase I Data for Alzheimer's Treatment
Research Report
Mass. Biotech Shares Strong Q3 Results
Research Report
Boston Biotech Announces Novartis Collaboration
Research Report
Regenerative Medicine Co. May Have Solution to Delivering Cell Treatments
This Canadian life sciences firm is developing an implantable cell-containing pouch, shown in clinical trial data thus far to be safe, well-tolerated and effective. Learn why several analysts rate the company Buy.H.C. Wainwright & Co. Raises Price Target on Biotech Following Positive Regulatory Updates
Research Report
DBV Technologies SA (DBVT:NASDAQ) received a raised target price after it released long-awaited regulatory clarity regarding the path forward for its Viaskin Peanut patch. Silver Break Out Confirmed
Contributed Opinion
The silver break out is confirmed, and Ron Struthers of Struthers Resource Stock Report expects a move to $50. He explains why he believes Coeur Mining Inc. (CDE:NYSE) offers good value and shares one biotech stock he believes is currently a sell. NY Biopharma Shares Promising Clinical Data
Research Report
Anavex Life Sciences Corp. (AVXL:NASDAQ) recently released encouraging preliminary electroencephalography (EEG) biomarker results from Part A of the ongoing Phase 2 clinical study of ANAVEX3-71 for schizophrenia treatment, according to an H.C. Wainright & Co. research note. H.C. Wainwright & Co. Shares Buy Rating on Biotech Co.
Research Report
H.C. Wainwright & Co. analysts gave Unicycive Therapeutics Inc. (UNCY:NASDAQ) a Buy rating after the company announced the successful completion of the Phase 1 study for UNI-494 in healthy volunteers. This article is issued on behalf of Treatment.com AI Inc. Is This AI Healthcare Stock Worth Being Overweight On?
Contributed Opinion Technical Analyst Clive Maund explains why he thinks Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) is a Strong Buy and worth being overweight on.
Mass. Biotech Receives FDA Approval
Research Report
Biofrontera Inc. (BFRI:NASDAQ) receieved FDA's approval of the company's supplemental Biologics License Application (sBLA) to expand the use of Ameluz for treating larger surface areas of actinic keratosis (AK) on the face and scalp, according to a Roth MKM research note. CT Biotech Ready for Clinical Milestones
Research Report
Trevi Therapeutics Inc. (TRVI:NASDAQ) has made progress in its clinical trials for Haduvio, particularly in treating chronic cough in idiopathic pulmonary fibrosis (IPF) patients and refractory chronic cough (RCC), according to an EF Hutton research note. Biotech Completes Last Patient Visit in Phase2b Osteosarcoma Trial
Research Report
Following OS Therapies Inc.'s (OSTX:NYSEAMERICAN) announcement that the last patient enrolled in their Phase 2b trial for OST-HER2 in recurred, resected Osteosarcoma (OS) has completed their final radiographical evaluation, the company received a Buy rating and high target price from EF Hutton. 
Streetwise Key Charts
